Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sarcoidosis, alveolar β-actin and pulmonary fibrosis.
Cooke G, Govender P, Watson CJ, Armstrong ME, O'Dwyer DN, Keane MP, King R, Tynan A, Dunn M, Donnelly SC. Cooke G, et al. Among authors: tynan a. QJM. 2013 Oct;106(10):897-902. doi: 10.1093/qjmed/hct160. Epub 2013 Jul 30. QJM. 2013. PMID: 23904517
Macrophage migration inhibitory factor enhances Pseudomonas aeruginosa biofilm formation, potentially contributing to cystic fibrosis pathogenesis.
Tynan A, Mawhinney L, Armstrong ME, O'Reilly C, Kennedy S, Caraher E, Jülicher K, O'Dwyer D, Maher L, Schaffer K, Fabre A, McKone EF, Leng L, Bucala R, Bernhagen J, Cooke G, Donnelly SC. Tynan A, et al. FASEB J. 2017 Nov;31(11):5102-5110. doi: 10.1096/fj.201700463R. Epub 2017 Aug 2. FASEB J. 2017. PMID: 28768722 Free PMC article.
Our in vivo studies demonstrate that utilizing a small-molecular-weight inhibitor targeting MIF's tautomerase activity (SCD-19) significantly reduces the inflammatory response in a murine pulmonary chronic P. aeruginosa model. ...Our novel findings support the conce …
Our in vivo studies demonstrate that utilizing a small-molecular-weight inhibitor targeting MIF's tautomerase activity (SCD-19) signi …
Macrophage migration inhibitory factor (MIF) enzymatic activity and lung cancer.
Mawhinney L, Armstrong ME, O' Reilly C, Bucala R, Leng L, Fingerle-Rowson G, Fayne D, Keane MP, Tynan A, Maher L, Cooke G, Lloyd D, Conroy H, Donnelly SC. Mawhinney L, et al. Among authors: tynan a. Mol Med. 2015 Apr 16;20(1):729-35. doi: 10.2119/molmed.2014.00136. Mol Med. 2015. PMID: 25826675 Free PMC article.
Aerosolized drug-loaded nanoparticles targeting migration inhibitory factors inhibit Pseudomonas aeruginosa-induced inflammation and biofilm formation.
Doroudian M, O'Neill A, O'Reilly C, Tynan A, Mawhinney L, McElroy A, Webster SS, MacLoughlin R, Volkov Y, E Armstrong M, A O'Toole G, Prina-Mello A, C Donnelly S. Doroudian M, et al. Among authors: a o toole g, tynan a. Nanomedicine (Lond). 2020 Dec;15(30):2933-2953. doi: 10.2217/nnm-2020-0344. Epub 2020 Nov 26. Nanomedicine (Lond). 2020. PMID: 33241979 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 35557082
The patient perspective on the environmental impact of inhalers.
Hodge A, Wickham H, Florman K, Barrowcliffe G, Tynan A, Patel A, Brill S, Brown J. Hodge A, et al. Among authors: tynan a. Respir Med. 2024 Dec;235:107864. doi: 10.1016/j.rmed.2024.107864. Epub 2024 Nov 18. Respir Med. 2024. PMID: 39566646
106 results